Breaking News, Collaborations & Alliances

Parexel To Handle Valeant NDA/MAA

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Valeant Pharmaceuticals International has appointed Parexel International to develop, coordinate and prepare the New Drug Application (NDA) and the European Marketing Authorization Application (MAA) for Valeant’s investigational compound retigabine. Retigabine is a novel neuronal potassium-channel opener that is being studied in Phase III trials as an adjunctive treatment for partial-onset seizures in patients with epilepsy. Valeant anticipates filing both applications in mid-2008. &#82...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters